Deep vein thrombosis

SonoVascular Enters into Strategic Collaboration with Lantheus Holdings, Inc. for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

Retrieved on: 
星期四, 五月 2, 2024
Safety, VTE, FIH, Partnership, Pulmonary embolism, Patient, DVT, Catheter, Microbubble, Vein, Coronary thrombosis, Deep vein thrombosis

VTE is a condition that occurs when a blood clot forms in a deep vein, resulting in DVT.

Key Points: 
  • VTE is a condition that occurs when a blood clot forms in a deep vein, resulting in DVT.
  • The microbubbles are activated by intravascular ultrasound and will be investigated in ongoing pre-clinical and upcoming clinical studies.
  • The SonoThrombectomy System has been engineered to address and overcome the deficiencies and limitations of current interventional devices.
  • Additionally, upon completion of a FIH study, SonoVascular has an option to enter into a long-term exclusive commercial supply agreement with Lantheus.

National Blood Clot Alliance Names Corewell Health a Center of Excellence

Retrieved on: 
星期三, 四月 10, 2024
Education, Patient, Hospital, VTE, Certification, NBCA, COE, Butterworth Hospital, Pulmonary embolism, Survivor, DVT, National Blood Clot Alliance, Health, Deep vein thrombosis, Coronary thrombosis, Nursing

PHILADELPHIA, April 10, 2024 /PRNewswire/ -- National Blood Clot Alliance ® (NBCA) today announced that Corewell Health™ Grand Rapids Hospitals – Butterworth Hospital has been named the inaugural NBCA Center of Excellence in the United States.

Key Points: 
  • PHILADELPHIA, April 10, 2024 /PRNewswire/ -- National Blood Clot Alliance ® (NBCA) today announced that Corewell Health™ Grand Rapids Hospitals – Butterworth Hospital has been named the inaugural NBCA Center of Excellence in the United States.
  • By designating Corewell Health a Center of Excellence, we are acknowledging its commitment to both clinical excellence and patient education," said Board Member and NBCA Committee Chair Justin Crockett.
  • In designating Corewell Health as an NBCA Center of Excellence, the committee highlighted both the qualitative and quantitative multidisciplinary, systematic approach to DVT and PE treatment.
  • "This formal recognition speaks highly of the demonstrated excellence of Corewell Health's program treating patients with acute and chronic VTE," said Alejandro Quiroga, M.D., president, Corewell Health in West Michigan.

Clarius and ThinkSono Introduce a New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs

Retrieved on: 
星期五, 四月 5, 2024
Cloud, CE marking, Diagnosis, Deep vein thrombosis, Algorithm, Partnership, Research, Class, AI, Patient, Leg, DVT, Temple Health, SDK, Marketing, Nursing, FDA, Clarius, Medical device

VANCOUVER, BC, April 5, 2024 /PRNewswire/ -- Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.

Key Points: 
  • ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.
  • ThinkSono Guidance enables non-ultrasound trained healthcare professionals to use the Clarius handheld ultrasound scanner to collect DVT exam data for a qualified clinician to review.
  • ThinkSono now uses Clarius' Solum software development kit (SDK), enabling the company to create a bespoke solution tailored to their DVT application.
  • The Clarius SDK suite empowers third party developers to seamlessly integrate AI-powered ultrasound software with Clarius handheld ultrasound systems, the Clarius App, and the Clarius Cloud exam management platform.

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Retrieved on: 
星期二, 三月 12, 2024
Deep vein thrombosis, Pulmonary embolism, VTE, Incidence, Sequela, CAVA, Patient, Post-thrombotic syndrome, Research, PTS, DVT, Randomized controlled trial, Safety, FACS, American Venous Forum, Data, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

Key Points: 
  • IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
  • The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
  • Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
  • We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”

MemorialCare Saddleback Medical Center Awarded Patient Safety Excellence Award from Healthgrades for the First Time

Retrieved on: 
星期五, 三月 22, 2024
Hospital, Healthgrades, Deep vein thrombosis, Pulmonary embolism, Organization, PSI, Patient, Safety, Patient safety, PSIS, Pressure ulcer, Physician, Nursing

LAGUNA HILLS, Calif., March 22, 2024 /PRNewswire/ -- MemorialCare Saddleback Medical Center was awarded the 2024 Patient Safety Excellence Award™ by Healthgrades , the leading resource that connects consumers, physicians and health systems.

Key Points: 
  • LAGUNA HILLS, Calif., March 22, 2024 /PRNewswire/ -- MemorialCare Saddleback Medical Center was awarded the 2024 Patient Safety Excellence Award™ by Healthgrades , the leading resource that connects consumers, physicians and health systems.
  • This award recognizes the top 10% of hospitals in the nation for patient safety.
  • "It is an honor to be named one of the top 10% of hospitals for patient safety for the first time," says Marcia Manker, chief executive officer, MemorialCare Saddleback Medical Center.
  • MemorialCare Saddleback Medical Center qualified for this recognition when it was named one of America's 250 Best Hospitals by Healthgrades in 2023.

Inovia Vein Calls for Increased Awareness Around Deep Vein Thrombosis Risks During DVT Awareness Month

Retrieved on: 
星期二, 三月 5, 2024
Health, Consumer, Women, Surgery, Seniors, Other Health, Men, Pulmonary embolism, Pacific Northwest, Education, Tenderness, Obesity, Pain, Deep vein thrombosis, Swelling, Leg, DVT, Pregnancy, Vein, Risk, Patient, Bed rest, Trauma, Cancer, Birth control

With March being nationally recognized as Deep Vein Thrombosis (DVT) Awareness Month , Inovia Vein , a leading provider of world-class vein health services, is calling for enhanced education and awareness about this potentially life-threatening condition.

Key Points: 
  • With March being nationally recognized as Deep Vein Thrombosis (DVT) Awareness Month , Inovia Vein , a leading provider of world-class vein health services, is calling for enhanced education and awareness about this potentially life-threatening condition.
  • Inovia Vein’s vein health experts are stepping up to spread the word about the condition.
  • “That said, at Inovia Vein, we believe every month should be ‘DVT Awareness Month,’ and we are dedicated to educating the communities we serve and beyond about prevention and education.
  • Inovia Vein, the leading provider of vein health services, is dedicated to offering comprehensive and compassionate care to patients with venous disorders.

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Retrieved on: 
星期二, 二月 20, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Safety, Deep vein thrombosis, Bayer, DVT, Patient, SIRIUS, Executive Committee, Pharmaceutical industry

Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).

Key Points: 
  • Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).
  • The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high medical relevance.
  • "We are excited to advance our anti-α2ap antibody to the next stage of clinical development in patients with deep vein thrombosis,” said Christian Rommel, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development.
  • Following the successful first-in-human trial, the goal of the randomized, double-blind, placebo-controlled, multi-center Phase II study (SIRIUS study) is to assess the efficacy and safety of BAY3018250 in patients with symptomatic proximal deep vein thrombosis.

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

Retrieved on: 
星期三, 二月 21, 2024
Thermal, Bangladesh Technical Education Board, Pulmonary embolism, Hypotension, Mallinckrodt, Anemia, Month, NIH, PUVA, Meta-analysis, Erythroderma, Excipient, Safety, PUVA therapy, Pain, Infection, Quality of life (healthcare), Deep vein thrombosis, Photopheresis, Artifact, FFS, ECP, Risk, OS, Graft-versus-host disease, Society, Extracorporeal, Methoxsalen, Patient, Systematic review, Burns, Transplant, Massachusetts General Hospital, Sunlight, Literature, Clutch (eggs), Environment, Pharmaceutical industry

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the safety, efficacy, and real-world outcomes of extracorporeal photopheresis (ECP) treatment for patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 An analysis of 47 studies reporting on the THERAKOS™ CELLEX™ Photopheresis System showed that treatment of SR-cGvHD with ECP was associated with improvements in patients' overall survival (OS), failure-free survival (FFS), and overall response rate (ORR).1 The results will be shared in a poster presentation at the 2024 Tandem Meetings, the combined Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 21-24, 2024 in San Antonio, TX.

Key Points: 
  • Skin-specific response at Months 2-3 and at Months 4-6 were 34.86% (95% CI: 13.26-65.21) and 54.22% (95% CI: 35.67-71.67), respectively.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to THERAKOS ECP.
  • THERAKOS™ Photopheresis is contraindicated in:
    THERAKOS™ Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available.
  • Please refer to the THERAKOS™ CELLEX™ Photopheresis System Operator Manual for a complete list of warnings and precautions and adverse events.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
星期三, 二月 14, 2024
Investigational New Drug, Peripheral edema, Anemia, Gastroenteritis, Medicine, Periodic breathing, Leukopenia, Diarrhea, Quality of life, Cough, Dizziness, Deep vein thrombosis, Nausea, Vomiting, DVT, Common, Tremor, Back pain, Constipation, Safety, Dexamethasone, First grade, Lower respiratory tract infection, URTI, Bronchitis, Therapy, Fatigue, Bortezomib, Pharmacokinetics, Thrombocytopenia, Rash, Patient, Neutropenia, Acceleration, Multiple myeloma, RMOC, IND, Insomnia, Lenalidomide, Appetite, Abdominal pain, Weakness, Pharmaceutical industry

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Studies Explore: Semaglutide Use and Its Impact on Total Hip Arthroplasty Postoperative Outcomes

Retrieved on: 
星期一, 二月 12, 2024
Facial muscles, Diabetes, SAN, Pulmonary embolism, Barnes-Jewish Hospital, Infection, Shock, MD, Obesity, Wound healing, Weight loss, Female, Osteopenia, Deep vein thrombosis, Respiratory failure, Risk, Type 2 diabetes, Attention, BMI, THA, Pearl, Patient, MPH, Opioid, Interview, Mortality, AAOS, Medicine, Long School, American Academy, Dentistry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Ozempic and Wegovy, which both contain the active ingredient semaglutide, have received recent attention in the media and on social platforms for its effectiveness in supporting weight loss. Ozempic, which is approved for people with Type 2 diabetes, has now become a widely accepted choice for weight loss, and Wegovy was approved in 2021 for long-term weight management.

Key Points: 
  • As the use of semaglutide increases among patients for diabetes and/or weight management, it's important to understand how it can impact postoperative outcomes of joint replacement surgery.
  • Two studies presented at the AAOS 2024 Annual Meeting looked at the use of semaglutide and its impact on outcomes of total hip arthroplasty (THA), finding that patients who take semaglutide at the time of THA experience similar postoperative outcomes to those who do not take the drug.
  • The researchers found that postoperative complications after THA are similar between obese patients using semaglutide compared to those who did not.
  • Both cohorts experienced a similar risk of hip arthroplasty revision, prosthesis infection, opioid-related disorders, surgical site infections, mortality, respiratory failure, pulmonary embolism, deep vein thrombosis, postoperative dehydration, cardiovascular comorbidities, shock, and prosthesis dislocations.